Article thumbnail

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment

By Anna Ferrari, Ilaria Tiraferri, Laura Neri and Emilio Sternieri


Triptans, selective 5-HT1B/1D receptor agonists, are specific drugs for the acute treatment of migraine that have the same mechanism of action. Here, it is discussed why the differences among kinetic parameters of oral triptans have proved not to be very important in clinical practice. There are three main reasons: (1) the differences among the kinetic parameters of oral triptans are smaller than what appears from their average values; (2) there is a large inter-subject, gender-dependent, and intra-subject (outside/during the attack) variability of kinetic parameters related to the rate and extent of absorption, i.e., those which are considered as critical for the response; (3) no dose-concentration–response curves have been defined and it is, therefore, impossible both to compare the kinetics of triptans, and to verify the objective importance of kinetic differences; (4) the importance of kinetic differences is outweighed by non-kinetic factors of variability of response to triptans. If no oral formulations are found that can allow more predictable pharmacokinetics, the same problems will probably also arise with new classes of drugs for the acute treatment of migraine

Topics: Review Article
Publisher: Springer Milan
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1996). 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
  2. (1989). 5-HT(1)-like receptor agonists and the pathophysiology of migraine.
  3. (1998). 5-HT1B/1D agonists in migraine: comparative pharmacology and its therapeutic implications.
  4. (2004). A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg) and zolmitriptan 2.5 mg) in the acute treatment of migraine.
  5. (1980). A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method.
  6. (1997). A study to determine the absolute bioavailability of naratriptan [abstract].
  7. (2001). Advances in pharmacological treatment of migraine.
  8. (2001). Almotriptan in the treatment of migraine.
  9. (2002). Almotriptan: a review of its use in migraine.
  10. (2002). Clinical pharmacokinetics of frovatriptan. Headache 42(Suppl 2):S54–S62
  11. (2001). Comparative aspects of triptans in treating migraine.
  12. (1988). Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.
  13. (2008). Cumulative lifetime migraine incidence in women and men.
  14. (2006). Dahlo ¨f C
  15. Dahlo ¨f CG (2002) Is there a preferred triptan? Headache 42:1–7
  16. (2005). Defining response in migraine: which endpoints are important?
  17. (1998). Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.
  18. (1989). Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Cephalalgia 9(Suppl 9):57–62
  19. (2009). Early treatment of acute migraine: new evidence of benefits.
  20. (2006). Eletriptan: a review of its use in the acute treatment of migraine.
  21. (2009). Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
  22. (2007). Gastric stasis occurs spontaneous, visually induced, and interictal migraine.
  23. (2002). Headache recurrence and treatment.
  24. (2009). Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
  25. (2002). Integrating the triptans into clinical practice.
  26. (2008). Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
  27. (2007). Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability.
  28. (1991). Mechanism of gastric emptying of a nondisintegrating radiotelemetry capsule in man.
  29. (1978). Migraine and drug absorption.
  30. (2009). Migraine and functional impairment.
  31. (2003). Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.
  32. (2001). Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist.
  33. (1997). Naratriptan oral pharmacokinetics in migraine subjects [abstract].
  34. (2005). Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 9:206–212
  35. (2004). Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation.
  36. (1997). Oral naratriptan tablets (2.5–1.0 mg) exhibit dose-proportional pharmacokinetics [abstract].
  37. (1995). Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study.
  38. (1999). Oral sumatriptan pharmacokinetics in the migraine state.
  39. (1991). Oral sumatriptan pharmacokinetics in the migrainous state.
  40. (1994). Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.
  41. (2001). Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
  42. (2007). Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment.
  43. (2010). Pharmacoepidemiology of triptans in a headache centre.
  44. (2007). Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment.
  45. (2005). Pharmacokinetic opportunities for combination therapy in migraine.
  46. (2004). Pharmacokinetic profile of a new form
  47. (1999). Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.
  48. (1999). Pharmacokinetics of rizatriptan tablets during and between migraine attacks.
  49. (2006). Prediction of headache response in migraine treatment.
  50. (2008). Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database.
  51. (2010). Quantifying the return of headache in triptan-treated migraineurs: an observational study.
  52. (2008). Relevance of absorption rate and lag time to the onset of action in migraine.
  53. (2005). Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan.
  54. (2006). Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
  55. (2000). Rizatriptan, a novel 5-HT1B/!D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects.
  56. (2010). Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
  57. (2007). Satisfaction with current migraine therapy: experience from 3 centers
  58. (1995). Single dose pharmacokinetics of sumatriptan in healthy volunteers.
  59. (1994). Sumatriptan clinical pharmacokinetics.
  60. (1996). Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache.
  61. (2003). Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs.
  62. (1991). The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan.
  63. (2005). The efficacy of treatment: therapy or therapist? Clin Med 5:309–310
  64. (1998). The rizatriptan multiple attack study group
  65. (2010). The serotonin gene polymorphism Stin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients.
  66. (2005). The use of multiattribute decision models in evaluating triptan treatment options in migraine.
  67. (2005). Triptan nonresponder studies: implications for clinical practice.
  68. (2010). Triptan therapy in migraine.
  69. (2005). Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect.
  70. (2001). Triptans are all different.
  71. (2000). Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
  72. (1997). Warrander A
  73. (2000). Within-patient consistency of response of rizatriptan for treating migraine.